文献速递肝胆胰外科

腹腔镜肝切除作为肝细胞癌初次治疗的长期结果:解剖性切除中外科医生的作用

Long-term results of laparoscopic liver resection for the primary treatment of hepatocellular carcinoma: role of the surgeon in anatomical resection.
PubMed 文献 · Surg Endosc · 2018-04-24

该回顾性研究分析了234例因肝细胞癌接受初次腹腔镜肝切除(均由同一外科医生完成)患者的长期随访数据,中位随访38个月。结果显示1、3、5年总生存率分别为98.3%、91.7%、87.1%,无复发生存率分别为82.1%、67.5%、55.3%。解剖性切除是复发的保护因素(多因素HR 0.59,95%CI 0.38-0.94,p=0.025)。

要点

  • 腹腔镜肝切除可作为肝功能良好肝细胞癌患者的初次治疗选择。
  • 解剖性切除与更低的复发风险独立相关(多因素HR 0.59)。
  • 5年总生存率87.1%,无复发生存率55.3%。

核心结论

  • 腹腔镜肝切除是肝功能良好且解剖结构合适的肝细胞癌患者可接受的初次治疗,与改善的预后相关。
  • 通过解剖性切除,腹腔镜肝切除可获得更低的复发率。

主要发现

  • 患者平均年龄55.63岁(范围31-76岁),男性167例。
  • 中位随访时间38个月(范围6-116个月)。
  • 227例(97.0%)患者为Child-Turcotte-Pugh A级。
  • 167例(71.4%)接受解剖性切除,63例(28.6%)接受非解剖性部分肝切除。
  • 1、3、5年总生存率分别为98.3%、91.7%、87.1%;无复发生存率分别为82.1%、67.5%、55.3%。

关键数值与推荐

  • Cox回归分析中,解剖性切除是复发的保护因素:单因素分析HR 0.49(95%CI 0.31-0.75,p=0.001),多因素分析HR 0.59(95%CI 0.38-0.94,p=0.025)。

临床怎么用

  • 对于肝功能良好且解剖结构合适的肝细胞癌患者,可考虑腹腔镜肝切除作为初次治疗。
  • 在技术可行时,优先选择解剖性切除以降低复发风险。

局限性

  • 回顾性研究设计。
  • 单中心、单外科医生经验,结果可能受外科医生技术影响。
  • 随访时间范围较宽(6-116个月),中位随访38个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver resection is a potentially curative therapy for hepatocellular carcinoma (HCC). LLR is a newly developed and safe technique associated with shorter hospital stay, less pain, better cosmetic outcomes, and similar complication rates as open surgery; however, data on its long-term outcomes remain scarce. METHODS: We retrospectively examined the clinical and follow-up data of 234 patients who underwent LLR (performed by a single surgeon in all cases) for the primary treatment of HCC between July 2007 and December 2015 at Asan Medical Center. RESULTS: The mean patient age was 55.63 (range 31-76) years; 167 were men. The median follow-up duration was 38 (range 6-116) months. A total of 227 patients (97.0%) had Child-Turcotte-Pugh grade A disease. Of them, 167 (71.4%) underwent anatomical resections and 63 (28.6%) underwent non-anatomical partial hepatectomies. Overall survival rates were 98.3, 91.7, and 87.1%, and recurrence-free survival rates were 82.1, 67.5, and 55.3% at 1, 3, and 5 years, respectively. In Cox regression analysis, anatomical resection was a risk factor for recurrence (univariate analysis: hazard ratio [HR] 0.49; 95% confidence interval [CI] 0.31-0.75; p = 0.001; multivariate analysis: HR 0.59; 95% CI 0.38-0.94; p = 0.025). CONCLUSIONS: LLR is an acceptable primary treatment for patients with HCC with good hepatic function and with an appropriate anatomical structure, and is associated with improved prognosis. LLR can achieve lower recurrence rates through anatomical resection.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Kang WH, Kim KH, Jung DH, et al. Long-term results of laparoscopic liver resection for the primary treatment of hepatocellular carcinoma: role of the surgeon in anatomical resection. Surg Endosc. 2018. PMID: 29691651. doi:10.1007/s00464-018-6194-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。